Phase 1 Targeted Combination Trial Of PF-00299804 And CP-751,871 In Patients With Advanced Solid Tumors.

Trial Profile

Phase 1 Targeted Combination Trial Of PF-00299804 And CP-751,871 In Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Oct 2016

At a glance

  • Drugs Dacomitinib (Primary) ; Figitumumab (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 12 Oct 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 24 Jul 2012 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 04 May 2012 Planned end date changed from 1 Jun 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top